Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

Liver International

Volumn 34, Issue 2, 2014, Pages 197-203

  Lens, Sabela ^a   Leoz, María ^a   Nazal, Leyla ^a   Bruguera, Miguel ^a   Parés, Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

(PPAR ) agonist; Chronic cholestasis; Liver stiffness; Primary biliary cirrhosis; Ursodeoxycholic acid therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BEZAFIBRATE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BLEEDING; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELASTOGRAPHY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEARTBURN; HEPATIC ENCEPHALOPATHY; HUMAN; JAUNDICE; LIVER DISEASE; NAUSEA; PILOT STUDY; PRIMARY BILIARY CIRRHOSIS; PROTHROMBIN TIME; PRURITUS; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL;

(PPARΑ) AGONIST; CHRONIC CHOLESTASIS; LIVER STIFFNESS; PRIMARY BILIARY CIRRHOSIS; URSODEOXYCHOLIC ACID THERAPY;

ALKALINE PHOSPHATASE; BEZAFIBRATE; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84891827040     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12290     Document Type: Article

References (32)

1. EASL Clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
2. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
3. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-20.
4. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-7.
5. Kuiper EM, Hansen BE, De Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-7.
6. Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117: 918-25.
7. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 31: 318-23.
8. Battezzati PM, Zuin M, Crosignani A, et al. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther 2001; 15: 1427-34.
9. Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005; 42: 1184-93.
10. Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 32: 897-900.
11. Mason AL, Luketic VA, Lindor KD, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (INT-747) to ursodeoxycholic acid. Hepatology 2010; 52: 357A.
12. Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000; 95: 2990-2.
13. Miyaguchi S, Ebinuma H, Imaeda H, et al. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 2000; 47: 1518-21.
14. Nakai S, Masaki T, Kurokohchi K, et al. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000; 95: 326-7.
15. Ohmoto K, Mitsui Y, Yamamoto S. Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver 2001; 21: 223-4.
16. Yano K, Kato H, Morita S, et al. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 2002; 97: 1075-7.
17. Ohira H, Sato Y, Ueno T, Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 2002; 97: 2147-9.
18. Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003; 38: 573-8.
19. Dohmen K, Mizuta T, Nakamuta M, et al. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10: 894-8.
20. Itakura J, Izumi N, Nishimura Y, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 2004; 29: 216-22.
21. Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008; 38: 557-64.
22. Walker LJ, Newton J, Jones DE, Bassendine M. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009; 49: 337-8.
23. Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2010; 44: 371-3.
24. Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2010; 33: 235-42.
25. Kowdley KV, Luketic VA, Jones DE, et al. The first new monotherapy therapeutic PBC study in a decade? An International study evaluating the farnesoid X receptor agonist obeticholic acid in PBC. Hepatology 2011; 54: 416A-7A.
26. Gebel T, Arand M, Oesch F. Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver. FEBS Lett 1992; 309: 37-40.
27. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-25.
28. Thulin P, Rafter I, Stockling K, et al. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol Appl Pharmacol 2008; 231: 1-9.
29. Roglans N, Vazquez-Carrera M, Alegret M, et al. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol 2004; 59: 855-61.
30. Matsumoto T, Miyazaki H, Nakahashi Y, et al. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004; 30: 125-36.
31. Chianale J, Vollrath V, Wielandt AM, et al. Fibrates induce mdr2 gene expression biliary phospholipid secretion in the mouse Biochem J 1996; 314: 781-6.
32. Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013; 57: 1931-41.